ETHOS
2020
Budesonide/Glycopyrrolate/Formoterol Triple Therapy in COPD
In 8,509 patients with moderate-to-very-severe COPD, budesonide/glycopyrrolate/formoterol (BGF 320/18/9.6 µg) reduced annual exacerbations compared with LAMA/LABA (GFF) and LABA/ICS (BFF).
Result
Primary endpoint: Annual rate of moderate or severe exacerbations
BGF 320 vs GFF: RR 0.76 (95% CI 0.69–0.83); vs BFF: RR 0.87 (0.79–0.95). All-cause mortality BGF 320 vs GFF HR 0.54 (0.34–0.87).
- Subtopic
- Single-inhaler triple
- Design
- Multicentre RCT, 4-arm
- Relevance
- Important: one of several pillars.
- Cited in
- GOLD 2023 COPD
- Source
- Rabe KF, et al. N Engl J Med. 2020;383(1):35-48.doi 10.1056/NEJMoa1916046
Discussion & critique
Corroborates IMPACT mortality signal but shares the same ICS-withdrawal asymmetry critique.